Visweswaran Ravikumar
Overview
Explore the profile of Visweswaran Ravikumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao D, Ravikumar V, Leach T, Kraushaar D, Lauder E, Li L, et al.
Cell Stem Cell
. 2024 Sep;
31(10):1447-1464.e6.
PMID: 39232559
It remains unknown whether and how intestinal stem cells (ISCs) adapt to inflammatory exposure and whether the adaptation leaves scars that will affect their subsequent regeneration. We investigated the consequences...
2.
Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu Y, et al.
JCI Insight
. 2023 Jul;
8(15).
PMID: 37440313
Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies are adenocarcinomas with luminal differentiation. However, some...
3.
Ravikumar V, Xu T, Al-Holou W, Fattahi S, Rao A
IEEE/ACM Trans Comput Biol Bioinform
. 2023 Jun;
20(5):2920-2932.
PMID: 37276119
In this paper, we study the problem of inferring spatially-varying Gaussian Markov random fields (SV-GMRF) where the goal is to learn a network of sparse, context-specific GMRFs representing network relationships...
4.
Reddy P, Zhao D, Ravikumar V, Lauder E, Li L, Sun Y, et al.
Res Sq
. 2023 Mar;
PMID: 36945465
Intestinal stem cells (ISC) encounter inflammatory insults in immune mediated gastro-intestinal (GI) diseases. It remains unknown whether, and how, they adapt, and if the adaptation leaves scars on the ISCs...
5.
Scott A, Correa L, Edwards D, Sun Y, Ravikumar V, Andren A, et al.
Antioxid Redox Signal
. 2023 Feb;
39(13-15):942-956.
PMID: 36852494
Targeting tumor metabolism may improve the outcomes for patients with glioblastoma (GBM). To further preclinical efforts targeting metabolism in GBM, we tested the hypothesis that brain tumors can be stratified...
6.
Al-Holou W, Wang H, Ravikumar V, Shankar S, Oneka M, Fehmi Z, et al.
Neoplasia
. 2023 Jan;
36:100872.
PMID: 36621024
Purpose: Glioblastoma(GBM) is a lethal disease characterized by inevitable recurrence. Here we investigate the molecular pathways mediating resistance, with the goal of identifying novel therapeutic opportunities. Experimental Design: We developed...
7.
Haase S, Banerjee K, Mujeeb A, Hartlage C, Nunez F, Nunez F, et al.
J Clin Invest
. 2022 Sep;
132(22).
PMID: 36125896
Pediatric high-grade gliomas (pHGGs) are the leading cause of cancer-related deaths in children in the USA. Sixteen percent of hemispheric pediatric and young adult HGGs encode Gly34Arg/Val substitutions in the...
8.
Warner E, Li X, Rao G, Huse J, Traylor J, Ravikumar V, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2022 Sep;
2022:4938-4941.
PMID: 36085890
Glioma, characterized by neoplastic growth in the brain, is a life-threatening condition that, in most cases, ultimately leads to death. Typical analysis of glioma development involves observation of brain tissue...
9.
Sweha S, Chung C, Natarajan S, Panwalkar P, Pun M, Ghali A, et al.
Sci Transl Med
. 2021 Oct;
13(615):eabf7860.
PMID: 34644147
High-grade gliomas with arginine or valine substitutions of the histone H3.3 glycine-34 residue (H3.3G34R/V) carry a dismal prognosis, and current treatments, including radiotherapy and chemotherapy, are not curative. Because H3.3G34R/V...
10.
Peltier D, Radosevich M, Ravikumar V, Pitchiaya S, Decoville T, Wood S, et al.
Sci Transl Med
. 2021 Mar;
13(585).
PMID: 33731431
Mechanisms governing allogeneic T cell responses after solid organ and allogeneic hematopoietic stem cell transplantation (HSCT) are incompletely understood. To identify lncRNAs that regulate human donor T cells after clinical...